(±)-Naringenin

Naringetol®, Pelargidanon®, Salipurpol®, Salipurol®, Asahina®, Naringenine, (S)-Naringenin, YSO1
A Blocker of Vascular L-type CaV Channels
    Cat #: N-110
    Alternative Name Naringetol®, Pelargidanon®, Salipurpol®, Salipurol®, Asahina®, Naringenine, (S)-Naringenin, YSO1
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 272.25
    Purity: >98%
    Effective concentration 100 µM - 1mM.
      • (±)-Naringenin
    Chemical name (±)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, 4′,5,7-Trihydroxyflavanone.
    Molecular formula C15H12O5.
    CAS No.: 67604-48-2.
    Activity Vascular L-type blocker with IC50 = 100 µM1.
      • Saponara, S. et al. (2011) Br. J. Pharmacol. 164, 1684.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility Ethanol. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • (±)-Naringenin
        Alomone Labs (±)-Naringenin inhibits L-type Cacurrents expressed in Xenopus oocytes.
        A. Time course of CaV1.2/α2-δ1/β1 current inhibition by 1 mM (±)-Naringenin (#N-110). Currents were elicited by application of voltage ramps from a holding potential of -100 mV to +50 mV (100 msec). B. Superimposed example traces of current responses before and during perfusion of 1 mM (±)-Naringenin as indicated.
    References - Scientific background
    • 1. Bers, D.M. et al. (1999) Cardiovasc. Res. 42, 339.
    • 2. Cook, N.C. et al. (1996) J. Nutr. Biochem. 7, 66.
    • 3. Ritz, M.F. et al. (2008) J. Nutr. 138, 226.
    • 4. Scholz, E.P.  et al. (2010) Cardiovasc. Ther. 28, e46.
    • 5. Saponara, S. et al. (2011) Br. J. Pharmacol. 164, 1684.
      • Ca2+ influx via voltage-dependent L-type Ca2+ channels (CaV1.2) found in cardiac and vascular smooth muscle initiate contraction and contribute to the timing of the cardiac action potential1.

        Flavonoids are a widely distributed group of polyphenolic compounds characterized by a common benzo-γ-pyrone structure. They occur naturally in fruits and vegetables, mainly as flavonoid glycosides, and are thus important constituents of the human diet2. Treatment of rats with flavonoids for 1 week before brain ischemia ameliorated cerebral blood flow, reduced the neurotoxic release of excitatory amino acids and protected the brain against ischemic injury3. There is an increasing body of evidence that flavonoids can affect vascular tone and cardiac function by directly targeting cardiovascular ion channels4.

        (±)-Naringenin, a natural predominant flavanone, has a wide range of pharmacologic activities. It inhibits CaV1.2 channel currents (ICa1.2) with IC50 values of 100 µM5.

    Target L-type Ca2+ channels
    Last update: 23/09/2019

    (±)-Naringenin (#N-110) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use